4Pandit Jdanley D E,Schulte G K. Crystal structure of human squalene synthase[J].Biol Chem, 2000,275(39): 30610-30617.
5Ugawa T, Kakuta H, Moritani H, et al. Effect of YM-53601, a novel squalene synthase inhibitor on the clearance rate of plasma LDL and VLDL in hamsters[J]. Br J Pharmacol, 2002, 137 (4): 561-569.
6Ugawa T, Kakuta H, Moritani H, et al. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model[J]. Br J Pharmacol, 2002, 135 (6): 1572-1578.
7Sawada M, Matsuo M, Seki J. Inhibition of cholesterol synthesis causes both hypercholesterolemia and hypocholesterole mia in hamsters[]].Biol Pharm Bull,2002, 25 (12): 1577-1582.
8Binet J, Thomas D, Benmbarek A, et al. Structure activity relationships of new inhibitors of mammalian 2,3-oxide squalene cyclase designed from isoquinoline derivatives[J]. Chem Pharm Bull, 2002,50(3): 316-329.
10Parthasarathy S, Santanam N, Ramachandran S, et al. Oxidants and antioxidants in atherogenesis. An appraisal[J]. J Lipid Res, 1999, 40 (12), 2143-2157.
6[5]Barter P J,Kastelein J J.Targetingcholesterylester transfer protein for the prevention and management of cardiovascular disease[J].J Am Con Cardiol,2006,47 (3):492-499.
7Chilcott J,Tappenden P,Jones ML. A systematic review of the clinical effectiveness of piog-litazone in the treament of type 2 diabetes mellitus[J].Clinical Therapeutics,2001,(11):1792-1832.
8Park BH,Brayer B,He TC. Peroxisome proliferator-activated receptor:rates in homorigenesis and chemoprevention in human cancer[J].Current Opinion in Oncology,2001,(06):78-83.
